Yiming Wu

Cardiology

3841 Piper Street
Anchorage, AK 99508

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Discovery of Milvexian, a High-Affinity, Orally Bioavailable Inhibitor of Factor XIa in Clinical Studies for Antithrombotic Therapy.

Discovery of Milvexian, a High-Affinity, Orally Bioavailable Inhibitor of Factor XIa in Clinical Studies for Antithrombotic Therapy.

Journal: Journal of medicinal chemistry

Published: September 08, 2021

Milvexian, an orally bioavailable, small-molecule, reversible, direct inhibitor of factor XIa: In vitro studies and in vivo evaluation in experimental thrombosis in rabbits.

Milvexian, an orally bioavailable, small-molecule, reversible, direct inhibitor of factor XIa: In vitro studies and in vivo evaluation in experimental thrombosis in rabbits.

Journal: Journal of thrombosis and haemostasis : JTH

Published: August 23, 2021

Discovery of a High Affinity, Orally Bioavailable Macrocyclic FXIa Inhibitor with Antithrombotic Activity in Preclinical Species.

Discovery of a High Affinity, Orally Bioavailable Macrocyclic FXIa Inhibitor with Antithrombotic Activity in Preclinical Species.

Journal: Journal of medicinal chemistry

Published: May 28, 2020

Potent, Orally Bioavailable, and Efficacious Macrocyclic Inhibitors of Factor XIa. Discovery of Pyridine-Based Macrocycles Possessing Phenylazole Carboxamide P1 Groups.

Potent, Orally Bioavailable, and Efficacious Macrocyclic Inhibitors of Factor XIa. Discovery of Pyridine-Based Macrocycles Possessing Phenylazole Carboxamide P1 Groups.

Journal: Journal of medicinal chemistry

Published: December 14, 2019

Orally bioavailable amine-linked macrocyclic inhibitors of factor XIa.

Orally bioavailable amine-linked macrocyclic inhibitors of factor XIa.

Journal: Bioorganic & medicinal chemistry letters

Published: November 15, 2019

Structure based design of macrocyclic factor XIa inhibitors: Discovery of cyclic P1 linker moieties with improved oral bioavailability.

Structure based design of macrocyclic factor XIa inhibitors: Discovery of cyclic P1 linker moieties with improved oral bioavailability.

Journal: Bioorganic & medicinal chemistry letters

Published: May 23, 2019

Pyridazine and pyridazinone derivatives as potent and selective factor XIa inhibitors.

Pyridazine and pyridazinone derivatives as potent and selective factor XIa inhibitors.

Journal: Bioorganic & medicinal chemistry letters

Published: January 02, 2018

Discovery of a Parenteral Small Molecule Coagulation Factor XIa Inhibitor Clinical Candidate (BMS-962212).

Discovery of a Parenteral Small Molecule Coagulation Factor XIa Inhibitor Clinical Candidate (BMS-962212).

Journal: Journal of medicinal chemistry

Published: October 28, 2017

Macrocyclic factor XIa inhibitors.

Macrocyclic factor XIa inhibitors.

Journal: Bioorganic & medicinal chemistry letters

Published: June 28, 2017

Macrocyclic inhibitors of Factor XIa: Discovery of alkyl-substituted macrocyclic amide linkers with improved potency.

Macrocyclic inhibitors of Factor XIa: Discovery of alkyl-substituted macrocyclic amide linkers with improved potency.

Journal: Bioorganic & medicinal chemistry letters

Published: May 02, 2017

Structure-Based Design of Macrocyclic Factor XIa Inhibitors: Discovery of the Macrocyclic Amide Linker.

Structure-Based Design of Macrocyclic Factor XIa Inhibitors: Discovery of the Macrocyclic Amide Linker.

Journal: Journal of medicinal chemistry

Published: January 14, 2017

Neutral macrocyclic factor VIIa inhibitors.

Neutral macrocyclic factor VIIa inhibitors.

Journal: Bioorganic & medicinal chemistry letters

Published: December 14, 2016

Showing 1-12 of 13

Last Updated: 09/26/2026